<Important Notes>
The forward-looking statements contained in this presentation are based on the Company’s assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties. Accordingly, there is a possibility that actual results and development programs may differ largely from these forecasts, due to a variety of factors. This report contains information on pharmaceutical products (including those under development), and the content of this report is not intended for medical promotion or medical advice. This translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version shall prevail.
- December 4 2025 ASKA Pharmaceutical Launches LEUPRORELIN ACETATE SR FOR INJECTION KIT
- November 5 2025 PPMX and ASKA Pharmaceutical Sign Joint Research Agreement to Aim to Create New Antibody Drugs
- October 20 2025 ASKA Obtains Marketing Authorization of Emergency Contraceptive Pill NORLEVO® as Switch to OTC Use and Daiichi Sankyo Healthcare Handles Distribution and Sales
- September 24 2025 Personnel Change of ASKA Pharmaceutical
- August 22 2025 Personnel Changes of ASKA Pharmaceutical
- July 15 2025 Call for Drug Discovery Research Proposal 2025 of ASKA pharmaceutical
- July 14 2025 ASKA to Open ZEB Certified Community Center “arca” at its Iwaki Factory
- June 30 2025 ASKA Launches Oral Contraceptive Slinda® 28 Tablets in Japan
- June 25 2025 ASKA to Initiate Domestic Phase III Clinical Trial of Relugolix Combination Tablet for Endometriosis
- June 24 2025 Personnel Changes of ASKA Pharmaceutical Holdings Subsidiaries
- June 20 2025 Personnel Change of ASKA Pharmaceutical
- May 19 2025 ASKA Obtains Manufacturing and Marketing Approval for Oral Contraceptive Slinda® 28 Tablets in Japan
- May 15 2025 ASKA Files Application with Japanese Authorities for Manufacturing and Marketing Approval of Emergency Contraceptive Pill “NORLEVO” as Switch OTC Drug
- April 24 2025 Personnel Changes in Board Members and Corporate Officers of ASKA Pharmaceutical Holdings’ Subsidiaries
- April 24 2025 Change in Personnel and Member of Board of Directors’ Responsibilities of ASKA Pharmaceutical
- April 24 2025 Changes in Organizational, Personnel, and Member of Board of Directors’ Responsibilities of ASKA Pharmaceutical
- April 23 2025 ASKA Announces Phase III Clinical Trial Result of TRM-270
For the previous news releases, please refer to the website of ASKA Pharmaceutical Holdings Co., Ltd.


